“In line with our commitment to the care and improvement of human life, Eastside Medical Center is thrilled to partner with the Sarah Cannon team and the STRIVE research study,” stated Stephen Higgins, MD, Chief Medical Officer at Eastside Medical Center. “This study presents the opportunity to significantly enhance the care we provide to the women of our community in the future by helping develop a tool that we hope will facilitate the early detection of cancer at a more treatable stage.”
The study, sponsored by GRAIL, Inc., is seeking to enroll 120,000 women across participating sites. Women who volunteer to participate will provide a blood sample and complete a short questionnaire at the time of their regular screening mammogram. In addition, participants will be followed and their health records will be monitored for up to five years for new cancer diagnoses.
“By participating in this exciting research effort, women in our communities will help GRAIL scientists in their efforts to develop a test that is intended to enhance our ability to detect cancer at early and more treatable stages,” said Dax Kurbegov, MD, principal investigator of the STRIVE Study at Sarah Cannon and Vice President and Physician-in-Chief of Clinical Programs for Sarah Cannon. “The study is designed
to help identify tiny fragments of genomic material that may signal the presence of breast or other cancers, and may help guide healthcare decisions by providing more information and reducing uncertainty.”
The study is being offered to women undergoing screening mammograms at multiple Sarah Cannon locations. For more information on the STRIVE Study, to see the full list of participating sites or to learn if you might be eligible to join, women can visit JoinSTRIVE.com, email STRIVE@sarahcannon.com or call 1-833-I-STRIVE (833-478-7483).
